Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
DNLI Denali Therapeutics	$13.18 -2.7%	$13.84	$10.57 ▼ $33.33	$1.91B	1.49	1.11 million shs	1.21 million shs
HRMY Harmony Biosciences	$34.38 +1.0%	$31.54	$26.47 ▼ $41.61	$1.97B	0.82	608,730 shs	531,767 shs
KNSA Kiniksa Pharmaceuticals	$27.43 +0.9%	$23.62	$17.38 ▼ $28.56	$2.00B	0.07	492,080 shs	543,644 shs
TYRA Tyra Biosciences	$9.25	$9.26	$6.42 ▼ $29.60	$491.08M	1.17	267,571 shs	557,503 shs

Free Today: Your Guide to Smarter Options Trades

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
DNLI Denali Therapeutics	-2.66%	-1.79%	-20.84%	-20.41%	-26.94%
HRMY Harmony Biosciences	+0.97%	+0.61%	+16.66%	+1.57%	+17.22%
KNSA Kiniksa Pharmaceuticals	+0.92%	+2.01%	+1.71%	+35.26%	+46.92%
TYRA Tyra Biosciences	0.00%	-0.43%	-10.19%	-21.01%	-41.97%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
DNLI Denali Therapeutics	4.3758 of 5 stars	4.5	1.0	4.7	3.2	2.5	0.0
HRMY Harmony Biosciences	4.9578 of 5 stars	4.6	4.0	0.0	4.2	3.3	4.4
KNSA Kiniksa Pharmaceuticals	2.8092 of 5 stars	3.5	2.0	0.0	2.7	3.3	0.6
TYRA Tyra Biosciences	1.4108 of 5 stars	3.5	0.0	0.0	1.6	2.5	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
DNLI Denali Therapeutics	3.06	Buy	$33.71	155.80% Upside
HRMY Harmony Biosciences	3.11	Buy	$52.78	53.51% Upside
KNSA Kiniksa Pharmaceuticals	3.00	Buy	$38.80	41.45% Upside
TYRA Tyra Biosciences	3.00	Buy	$30.83	233.33% Upside

Current Analyst Ratings Breakdown

Latest TYRA, KNSA, HRMY, and DNLI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/21/2025	TYRA Tyra Biosciences	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$33.00
5/19/2025	DNLI Denali Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$28.00 ➝ $27.00
5/15/2025	HRMY Harmony Biosciences	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$44.00 ➝ $48.00
5/13/2025	HRMY Harmony Biosciences	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/8/2025	DNLI Denali Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$30.00 ➝ $29.00
5/7/2025	DNLI Denali Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/7/2025	DNLI Denali Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$80.00 ➝ $32.00
5/6/2025	HRMY Harmony Biosciences	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$49.00 ➝ $49.00
4/29/2025	KNSA Kiniksa Pharmaceuticals	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $45.00
4/28/2025	HRMY Harmony Biosciences	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$55.00 ➝ $48.00
4/24/2025	DNLI Denali Therapeutics	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy

(Data available from 5/31/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
DNLI Denali Therapeutics	$330.53M	5.79	N/A	N/A	$7.42 per share	1.78
HRMY Harmony Biosciences	$744.85M	2.65	$2.57 per share	13.38	$7.97 per share	4.31
KNSA Kiniksa Pharmaceuticals	$481.17M	4.16	N/A	N/A	$6.23 per share	4.40
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	$4.74 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
DNLI Denali Therapeutics	-$145.22M	-$2.67	N/A	N/A	N/A	N/A	-32.94%	-30.04%	7/31/2025 (Estimated)
HRMY Harmony Biosciences	$128.85M	$2.62	16.29	11.05	0.47	17.98%	23.16%	14.24%	8/5/2025 (Estimated)
KNSA Kiniksa Pharmaceuticals	$14.08M	-$0.25	N/A	109.72	N/A	-2.36%	-7.31%	-5.95%	7/22/2025 (Estimated)
TYRA Tyra Biosciences	-$69.13M	-$1.63	N/A	N/A	N/A	N/A	-24.56%	-23.31%	8/6/2025 (Estimated)

Latest TYRA, KNSA, HRMY, and DNLI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	TYRA Tyra Biosciences	-$0.49	-$0.47	+$0.02	-$0.47	N/A	N/A
5/6/2025	Q1 2025	DNLI Denali Therapeutics	-$0.71	-$0.78	-$0.07	-$0.78	$3.24 million	N/A
5/6/2025	Q1 2025	HRMY Harmony Biosciences	$0.59	$0.78	+$0.19	$0.78	$184.26 million	$184.73 million
4/29/2025	Q1 2025	KNSA Kiniksa Pharmaceuticals	$0.02	$0.11	+$0.09	$0.11	$128.35 million	$137.79 million
3/27/2025	Q4 2024	TYRA Tyra Biosciences	-$0.48	-$0.43	+$0.05	-$0.43	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
DNLI Denali Therapeutics	N/A	N/A	N/A	N/A	N/A
HRMY Harmony Biosciences	N/A	N/A	N/A	N/A	N/A
KNSA Kiniksa Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
TYRA Tyra Biosciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
DNLI Denali Therapeutics	N/A	9.98	9.98
HRMY Harmony Biosciences	0.28	3.24	3.20
KNSA Kiniksa Pharmaceuticals	N/A	3.24	2.95
TYRA Tyra Biosciences	N/A	29.55	29.55

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
DNLI Denali Therapeutics	92.92%
HRMY Harmony Biosciences	86.23%
KNSA Kiniksa Pharmaceuticals	53.95%
TYRA Tyra Biosciences	84.14%

Insider Ownership

Company	Insider Ownership
DNLI Denali Therapeutics	12.50%
HRMY Harmony Biosciences	23.60%
KNSA Kiniksa Pharmaceuticals	54.57%
TYRA Tyra Biosciences	15.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
DNLI Denali Therapeutics	430	145.28 million	132.55 million	Optionable
HRMY Harmony Biosciences	200	57.42 million	39.47 million	Optionable
KNSA Kiniksa Pharmaceuticals	220	72.97 million	32.80 million	Optionable
TYRA Tyra Biosciences	20	53.09 million	42.81 million	Optionable

TYRA, KNSA, HRMY, and DNLI Headlines

Recent News About These Companies

Millennium Management LLC Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 31 at 3:28 AM | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Trading 6.1% Higher - Here's Why

May 30 at 2:31 PM | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Now Covered by Piper Sandler

May 23, 2025 | marketbeat.com

HC Wainwright Has Optimistic Outlook of TYRA FY2025 Earnings

May 23, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Coverage Initiated at Piper Sandler

May 23, 2025 | americanbankingnews.com

Equities Analysts Offer Predictions for TYRA FY2026 Earnings

May 22, 2025 | marketbeat.com

FY2025 EPS Forecast for Tyra Biosciences Boosted by Analyst

May 22, 2025 | americanbankingnews.com

Vestal Point Capital LP Makes New Investment in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 21, 2025 | marketbeat.com

Dimensional Fund Advisors LP Increases Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 19, 2025 | marketbeat.com

Janus Henderson Group PLC Has $24.29 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 18, 2025 | marketbeat.com

Jacobs Levy Equity Management Inc. Purchases Shares of 244,245 Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 17, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Acquired by Orbimed Advisors LLC

May 15, 2025 | marketbeat.com

Cubist Systematic Strategies LLC Takes $1.53 Million Position in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 15, 2025 | marketbeat.com

Tyra Biosciences, Inc. (NASDAQ:TYRA) Given Average Rating of "Buy" by Brokerages

May 13, 2025 | marketbeat.com

Tyra Biosciences (NASDAQ:TYRA) Issues Quarterly Earnings Results, Beats Expectations By $0.02 EPS

May 12, 2025 | marketbeat.com

Tyra Biosciences to Participate at Upcoming Investor Conferences

May 12, 2025 | prnewswire.com

Farallon Capital Management LLC Invests $13.91 Million in Tyra Biosciences, Inc. (NASDAQ:TYRA)

May 11, 2025 | marketbeat.com

One Tyra Biosciences Insider Raised Stake By 284% In Previous Year

May 9, 2025 | finance.yahoo.com

54,783 Shares in Tyra Biosciences, Inc. (NASDAQ:TYRA) Acquired by Raymond James Financial Inc.

May 9, 2025 | marketbeat.com

Tyra Biosciences Reports First Quarter 2025 Financial Results and Highlights

May 8, 2025 | prnewswire.com

Why Tyra Biosciences, Inc.’s (TYRA) Stock Is Down 5.48%

May 6, 2025 | aaii.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TYRA, KNSA, HRMY, and DNLI Company Descriptions

Denali Therapeutics NASDAQ:DNLI

$13.18 -0.36 (-2.66%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$13.45 +0.27 (+2.05%)

As of 05/30/2025 07:03 PM Eastern

Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company's transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases. It also provides early stage program include TAK-594/DNL593 program for FTD-GRN; DNL126 program for MPS IIIA, a Sanfilippo Syndrome A; DNL622 for MPS I which is Hurler syndrome; Antibody Transport Vehicle Amyloid beta program; Oligonucleotide Transport Vehicle platform, a novel class of biotherapeutics to address the root cause of diseases through modulation of gene expression; and other TV-enabled discovery programs. The company has collaboration agreements with Biogen MA Inc. and Biogen International GmbH; Genzyme Corporation; Takeda Pharmaceutical Company Limited; F-star Gamma Limited, F-star Biotechnologische Forschungs-und Entwicklungsges m.b.H, and F-star Biotechnology Limited; and Genentech, Inc. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Harmony Biosciences NASDAQ:HRMY

$34.38 +0.33 (+0.97%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$34.88 +0.49 (+1.44%)

As of 05/30/2025 07:26 PM Eastern

Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.

Kiniksa Pharmaceuticals NASDAQ:KNSA

$27.43 +0.25 (+0.92%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$27.36 -0.07 (-0.26%)

As of 05/30/2025 04:21 PM Eastern

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.

Tyra Biosciences NASDAQ:TYRA

$9.25 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$8.94 -0.31 (-3.30%)

As of 05/30/2025 04:20 PM Eastern

Tyra Biosciences, Inc., a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions. Its lead product candidate is TYRA-300, which is in Phase 1/2 clinical trials for the treatment of patients with metastatic urothelial carcinoma and other solid tumors. The company is also developing TYRA-300 for skeletal conditions, including achondroplasia, hypochondroplasia, thanatophoric dysplasia, and other FGFR3-driven genetic syndromes; TYRA-200, a candidate in Phase 1 clinical trial for bile duct and solid tumors; and TYRA-430 for the treatment of hepatocellular carcinoma. The company was incorporated in 2018 and is headquartered in Carlsbad, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time